DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS

Human Biomarkers of Rapid Antidepressant Effects

(2013) Carlos A. Zarate et al.   BIOLOGICAL PSYCHIATRY

Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses

(2013) Bhavya Voleti et al.   BIOLOGICAL PSYCHIATRY

Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression

(2013) Allison C Nugent et al.   JOURNAL OF PSYCHOPHARMACOLOGY

2012 FDA drug approvals

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Neuroimaging in Psychiatric Pharmacogenetics Research: The Promise and Pitfalls

(2013) Mary Falcone et al.   NEUROPSYCHOPHARMACOLOGY

Potential of Pretreatment Neural Activity in the Visual Cortex During Emotional Processing to Predict Treatment Response to Scopolamine in Major Depressive Disorder

(2013) Maura L. Furey et al.   JAMA Psychiatry

Toward a Systems Biology of Mood Disorder

(2012) Andrew M. McIntosh   BIOLOGICAL PSYCHIATRY

Family history of alcohol dependence and antidepressant response to anN-methyl-D-aspartate antagonist in bipolar depression

(2012) David A Luckenbaugh et al.   BIPOLAR DISORDERS

Pharmacogenetically Driven Treatments for Alcoholism

(2012) Albert J. Arias et al.   CNS DRUGS

Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease

(2012) Na-Young Han et al.   Journal of Digestive Diseases

NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia

(2012) A. Anticevic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Data sharing in neuroimaging research

(2012) Jean-Baptiste Poline et al.   Frontiers in Neuroinformatics

Monitoring Ketamine Treatment Response in a Depressed Patient via Peripheral Mammalian Target of Rapamycin Activation

(2011) Magdalena C. Denk et al.   AMERICAN JOURNAL OF PSYCHIATRY

Using Computational Patients to Evaluate Illness Mechanisms in Schizophrenia

(2011) Ralph E. Hoffman et al.   BIOLOGICAL PSYCHIATRY

Acute Hydrocortisone Treatment Increases Anxiety but Not Fear in Healthy Volunteers: A Fear-Potentiated Startle Study

(2011) Christian Grillon et al.   BIOLOGICAL PSYCHIATRY

The size and burden of mental disorders and other disorders of the brain in Europe 2010

(2011) H.U. Wittchen et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease

(2011) James D. Lewis   GASTROENTEROLOGY

Surrogate markers of treatment outcome in major depressive disorder

(2011) George I. Papakostas   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a Pilot and Replication Study

(2011) G I Papakostas et al.   MOLECULAR PSYCHIATRY

Bring on the biomarkers

(2011) George Poste   NATURE

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

(2011) William E. Klunk   NEUROBIOLOGY OF AGING

Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental Disorders

(2010) Thomas Insel et al.   AMERICAN JOURNAL OF PSYCHIATRY

Clinical Implications of the Cytokine Hypothesis of Depression: The Association between Use of Statins and Aspirin and the Risk of Major Depression

(2010) Julie A. Pasco et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Is Pharma Running Out of Brainy Ideas?

(2010) G. Miller   SCIENCE

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Translational Medicine and the Value of Biomarker Qualification

(2010) F. M. Goodsaid et al.   Science Translational Medicine

Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

(2009) M.A. Karsdal et al.   BIOMARKERS

The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood Disorders

(2009) Rodrigo Machado-Vieira et al.   NEUROSCIENTIST

Family History of Alcohol Dependence and Initial Antidepressant Response to an N -methyl-D-aspartate Antagonist

(2008) Laura E. Phelps et al.   BIOLOGICAL PSYCHIATRY

Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine

(2008) Giacomo Salvadore et al.   BIOLOGICAL PSYCHIATRY

Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective

(2008) Shashi Amur et al.   Biomarkers in Medicine

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategic Approach to Fit-for-Purpose Biomarkers in Drug Development

(2007) John A. Wagner   Annual Review of Pharmacology and Toxicology